m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00980)
Name
Dactinomycin
Synonyms
1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine; 4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide; ACT D; ACTINOMYCIN D AMP; AD (VAN); Actactinomycin A IV; Actinomycin 11 cosmegen; Actinomycin 7; Actinomycin A IV; Actinomycin Aiv; Actinomycin C (sub1); Actinomycin C(sub1); Actinomycin C1; Actinomycin D (JP15); Actinomycin D deriv. of 3H-phenoxaocardazine; Actinomycin D, sodium deoxyribonucleic acid complex; Actinomycin I; Actinomycin I (sub1); Actinomycin I(sub 1); Actinomycin I(sub1); Actinomycin I1; Actinomycin IV; Actinomycin X 1; Actinomycin X1; Actinomycin cl; Actinomycin x i; Actinomycin-(threo-val-pro-sar-meval); Actinomycin-IV; Actinomycin-[threo-val-pro-sar-meval]; Actinomycindioic D acid, dilactone; Actinomyein-theo-val-pro-sar-meval; Acto-D; Antibiotic from Streptomyces parvullus; COSMEGEN (TN); Chounghwamycin B; Cosmegen; D Actinomycin; DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA; Dactinomicina; Dactinomicina [INN-Spanish]; Dactinomycin (USP); Dactinomycin D; Dactinomycin [USAN:BAN]; Dactinomycine; Dactinomycine [INN-French]; Dactinomycinum; Dactinomycinum [INN-Latin]; Dactinomyein d; Dilactone actin omycindioic D acid; Dilactone actinomycin D acid; Dilactone actinomycindioic D acid; GNF-PF-1977; HBF 386; HBF 386 meractinomycin; Lyovac cosmegen; Meractinomycin; NP-005932; O)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine; Oncostatin K; PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA; X 97
    Click to Show/Hide
Status
Approved
Structure
3D MOL
2D MOL
Formula
C62H86N12O16
InChI
1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)
InChIKey
RJURFGZVJUQBHK-UHFFFAOYSA-N
PubChem CID
2019
VARIDT Drug ID
DR01203
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Breast cancer resistance protein (ABCG2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Breast cancer resistance protein (ABCG2) is a therapeutic target for Dactinomycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dactinomycin through regulating the expression of Breast cancer resistance protein (ABCG2). [1], [2]
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Dactinomycin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Dactinomycin through regulating the expression of P-glycoprotein 1 (ABCB1). [3], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Dactinomycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dactinomycin through regulating the expression of P-glycoprotein 1 (ABCB1). [1], [4]
References
Ref 1 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.
Ref 2 Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72.
Ref 3 Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. eCollection 2021.
Ref 4 Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005 Feb;46(2):224-35.